英国医院中使用阿达木单抗治疗的溃疡性结肠炎患者的剂量升级和医疗资源利用：真实世界数据分析

数据集获取（Figshare）

• 源站标题：Dose Escalation and Healthcare Resource Use among Ulcerative Colitis Patients Treated with Adalimumab in English Hospitals: An Analysis of Real-World Data
• DOI：10.1371/journal.pone.0149692
• 发布日期：2016-02-26
• 文件数：2 个
• 文件总体积：589.58 KB
• 源站页面：https://plos.figshare.com/articles/dataset/Dose_Escalation_and_Healthcare_Resource_Use_among_Ulcerative_Colitis_Patients_Treated_with_Adalimumab_in_English_Hospitals_An_Analysis_of_Real_World_Data/3023992

命令行下载

curl -L -o "S1 Fig.tif" "https://ndownloader.figshare.com/files/4726027"
curl -L -o "S2 Fig.tif" "https://ndownloader.figshare.com/files/4726030"

文件清单

• S1 Fig.tif（294.81 KB）
• S2 Fig.tif（294.78 KB）

文件总体积 589.58 KB（源站 API 实测）。

数据加载示例（图像类）

from PIL import Image
import glob, os

files = (glob.glob(os.path.join(path, "**", "*.png"), recursive=True)
       + glob.glob(os.path.join(path, "**", "*.jpg"), recursive=True)
       + glob.glob(os.path.join(path, "**", "*.tif"), recursive=True))
print("图像文件数:", len(files))
img = Image.open(files[0]); print("尺寸/模式:", img.size, img.mode)

# torchvision Dataset 方式:
# from torchvision import datasets
# ds = datasets.ImageFolder(path)  # 要求 子目录=类别

目录组织与标注格式以源站说明和下载后实际文件为准。

数据说明

Objective
To describe the real-world use of adalimumab for maintenance treatment of ulcerative colitis (UC) and associated healthcare costs in English hospitals.
Design
Retrospective cohort study.
Setting
Analysis of NHS Hospital Episode Statistics linked with pharmacy dispensing data in English hospitals.
Patients
Adult UC patients receiving ≥240mg during adalimumab treatment induction, subsequently maintained on adalimumab.
Outcomes
Frequency and pattern of adalimumab use and dose escalation during maintenance treatment and associated healthcare costs (prescriptions and hospital visits).
Results
191 UC patients completed adalimumab treatment induction. 83 (43.46%) dose escalated during maintenance treatment by ≥100% (equivalent to weekly dosing) (median time to dose escalation: 139 days). 56 patients (67.47%) subsequently de-escalated by ≥50% (median time to dose de-escalation: 21 days). Mean all-cause healthcare costs for all patients ≤12 months of index were £13,892. Dose escalators incurred greater mean healthcare costs than non-escalators ≤12 months of index (£14,596 vs. £13,351). Prescriptions accounted for 96.49% of UC-related healthcare costs (£11,090 of £11,494 in all patients).
Conclusions
Within the cohort, 43.46% of UC patients escalated their adalimumab dose by ≥100% and incurred greater costs than non-escalators. The apparent underestimation of adalimumab dose escalation in previous studies may have resulted in underestimated costs in healthcare systems.

许可

CC BY 4.0

引用

学术使用请引用 DOI 10.1371/journal.pone.0149692（source: https://plos.figshare.com/articles/dataset/Dose_Escalation_and_Healthcare_Resource_Use_among_Ulcerative_Colitis_Patients_Treated_with_Adalimumab_in_English_Hospitals_An_Analysis_of_Real_World_Data/3023992）。